Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol for Anemia of CKD Trial (FACT)
2010-022133-28Phase 4Completed
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- May 2013
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferumoxytol in iron deficiency anemia (IDA), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoint: Change in hemoglobin after each treatment period over one year. Started May 2013; status: completed.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2010-022133-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022133-28.